Midsize Japanese Pharmas Seen As Major Drivers Of Merger Mania
This article was originally published in PharmAsia News
Midsize Japanese pharmaceuticals are seen as reaping most of the benefits of a global merger fever in the industry as foreign firms look to Japan for business opportunities. Japan does not expect to see a slowdown in the mergers-and-acquisition activity this year, following up on major merger activity of last year. An investment executive says midsize firms facing loss of patent protection for some of their drugs, plus government efforts to drive down the cost of drugs in Japan, will begin restructuring, including taking on M&As, to stay afloat and compete. (Click here for more - a subscription may be required
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.